• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人肝微粒体及纯化的细胞色素P-450同工酶中布呋洛尔1'-羟化酶、异喹胍4-羟化酶和右美沙芬O-脱甲基酶的高效液相色谱测定法

High-performance liquid chromatographic assays for bufuralol 1'-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver.

作者信息

Kronbach T, Mathys D, Gut J, Catin T, Meyer U A

出版信息

Anal Biochem. 1987 Apr;162(1):24-32. doi: 10.1016/0003-2697(87)90006-6.

DOI:10.1016/0003-2697(87)90006-6
PMID:3605590
Abstract

Bufuralol, debrisoquine, and dextromethorphan are three prototype substrates of the common genetic deficiency of oxidative drug metabolism in man known as debrisoquine/sparteine-type polymorphism. We describe assays for the in vitro metabolism of (+)- and (-)-bufuralol, debrisoquine, and dextromethorphan in human liver microsomes and reconstituted purified cytochrome P-450 isozymes. These assays combine nonextractive sample preparation by precipitation of protein with perchloric acid with reversed-phase inorganic ion-pair HPLC and fluorescence detection. The minimal detectable levels of the major metabolites formed are 1'-hydroxybufuralol, 0.1 ng/ml; 4-hydroxydebrisoquine, 0.8 ng/ml; and dextrorphan, 0.1 ng/ml. Formation of these metabolites is linear for at least 45 min and between 1 and 100 micrograms of microsomal protein. Comparative kinetic analysis of the three monooxygenase reactions in human liver microsomes revealed an apparent biphasicity of (+)- and (-)-bufuralol 1'-hydroxylation and dextromethorphan O-demethylation but monophasic formation of 4-hydroxydebrisoquine in the substrate concentration range (less than 1 mM) studied. These data, in combination with those obtained by purified human cytochrome P-450 isozymes indicate the involvement of the same enzyme in the metabolism of all three substrates investigated. However, additional and distinct activities contribute to the metabolism of (+)- and (-)-bufuralol and dextromethorphan.

摘要

布呋洛尔、异喹胍和右美沙芬是人类中常见的氧化药物代谢遗传缺陷的三种原型底物,这种遗传缺陷被称为异喹胍/鹰爪豆碱型多态性。我们描述了在人肝微粒体和重组纯化细胞色素P-450同工酶中对(+)-和(-)-布呋洛尔、异喹胍及右美沙芬进行体外代谢的检测方法。这些检测方法将用高氯酸沉淀蛋白质的非萃取性样品制备方法与反相无机离子对高效液相色谱法及荧光检测相结合。所形成的主要代谢物的最低可检测水平分别为:1'-羟基布呋洛尔,0.1 ng/ml;4-羟基异喹胍,0.8 ng/ml;及右啡烷,0.1 ng/ml。这些代谢物的形成在至少45分钟内以及1至100微克微粒体蛋白之间呈线性。对人肝微粒体中三种单加氧酶反应的比较动力学分析显示,(+)-和(-)-布呋洛尔1'-羟基化及右美沙芬O-去甲基化呈现明显的双相性,但在所研究的底物浓度范围(小于1 mM)内,4-羟基异喹胍的形成呈单相性。这些数据与通过纯化的人细胞色素P-450同工酶获得的数据相结合,表明所研究的所有三种底物的代谢均涉及同一种酶。然而,额外且不同的活性对(+)-和(-)-布呋洛尔及右美沙芬的代谢也有贡献。

相似文献

1
High-performance liquid chromatographic assays for bufuralol 1'-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver.人肝微粒体及纯化的细胞色素P-450同工酶中布呋洛尔1'-羟化酶、异喹胍4-羟化酶和右美沙芬O-脱甲基酶的高效液相色谱测定法
Anal Biochem. 1987 Apr;162(1):24-32. doi: 10.1016/0003-2697(87)90006-6.
2
Bufuralol, dextromethorphan, and debrisoquine as prototype substrates for human P450IID6.布呋洛尔、右美沙芬和异喹胍作为人P450IID6的原型底物。
Methods Enzymol. 1991;206:509-17. doi: 10.1016/0076-6879(91)06120-r.
3
Debrisoquine/sparteine-type polymorphism of drug oxidation. Purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol.药物氧化的异喹胍/鹰爪豆碱型多态性。参与原型底物布呋洛尔羟化受损的两种功能不同的人肝细胞色素P-450同工酶的纯化与特性鉴定。
J Biol Chem. 1986 Sep 5;261(25):11734-43.
4
Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes.人肝微粒体中细胞色素P450 2D6和1A2酶对布呋洛尔的羟基化作用。
Mol Pharmacol. 1994 Sep;46(3):568-77.
5
Cytochrome P450IID subfamily in non-human primates. Catalytical and immunological characterization.
Biochem Pharmacol. 1991 Jun 1;41(11):1657-63. doi: 10.1016/0006-2952(91)90166-3.
6
The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation.药物氧化两种常见多态性的分子机制——催化布呋洛尔和美芬妥因氧化的细胞色素P-450同工酶功能改变的证据
Xenobiotica. 1986 May;16(5):449-64. doi: 10.3109/00498258609050251.
7
Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidation. Characterization of bufuralol 1'-hydroxylation in liver microsomes of in vivo phenotyped carriers of the genetic deficiency.药物氧化的去甲丙咪嗪/鹰爪豆碱型遗传多态性的酶学基础。对遗传缺陷的体内表型携带者肝脏微粒体中布呋洛尔1'-羟化作用的表征。
Biochem Pharmacol. 1987 Dec 1;36(23):4145-52. doi: 10.1016/0006-2952(87)90573-9.
8
Catalytic specificity of CYP2D isoforms in rat and human.大鼠和人类中CYP2D亚型的催化特异性
Drug Metab Dispos. 2002 Sep;30(9):970-6. doi: 10.1124/dmd.30.9.970.
9
Genetic polymorphism in drug oxidation: in vitro studies of human debrisoquine 4-hydroxylase and bufuralol 1'-hydroxylase activities.药物氧化中的基因多态性:人异喹胍4-羟化酶和丁呋洛尔1'-羟化酶活性的体外研究
Biochem Pharmacol. 1985 Jan 1;34(1):65-71. doi: 10.1016/0006-2952(85)90101-7.
10
Selective inhibition of major drug metabolizing cytochrome P450 isozymes in human liver microsomes by carbon monoxide.
Life Sci. 1994;54(14):951-6. doi: 10.1016/0024-3205(94)00496-x.

引用本文的文献

1
Proof of principle concept for the analysis and functional prediction of rare genetic variants in the CYP2C19 and CYP2D6 genes.CYP2C19和CYP2D6基因罕见遗传变异分析及功能预测的原理验证概念
Hum Genomics. 2025 May 28;19(1):62. doi: 10.1186/s40246-025-00765-2.
2
Improved Prediction of CYP2D6 Catalyzed Drug Metabolism by Taking Variant Substrate Specificities and Novel Polymorphic Haplotypes into Account.通过考虑变异底物特异性和新型多态性单倍型改进对CYP2D6催化的药物代谢的预测
Clin Pharmacol Ther. 2025 Jul;118(1):218-231. doi: 10.1002/cpt.3680. Epub 2025 Apr 22.
3
KM-408, a novel phenoxyalkyl derivative as a potential anticonvulsant and analgesic compound for the treatment of neuropathic pain.
KM-408,一种新型苯氧烷基衍生物,作为一种有潜力的抗惊厥和镇痛化合物,用于治疗神经性疼痛。
Pharmacol Rep. 2023 Feb;75(1):128-165. doi: 10.1007/s43440-022-00431-7. Epub 2022 Nov 19.
4
Effects of dapagliflozin in combination with insulin on cytochrome P450 activities in a diabetes type 1 rat model.达格列净联合胰岛素对 1 型糖尿病大鼠细胞色素 P450 活性的影响。
J Vet Med Sci. 2021 Oct 21;83(10):1597-1603. doi: 10.1292/jvms.21-0249. Epub 2021 Sep 6.
5
Effects of several organophosphates on hepatic cytochrome P450 activities in rats.几种有机磷酸酯对大鼠肝脏细胞色素P450活性的影响。
J Vet Med Sci. 2020 May 15;82(5):598-606. doi: 10.1292/jvms.19-0452. Epub 2020 Mar 25.
6
Effect of Benifuuki Tea on Cytochrome P450-mediated Metabolic Activity in Rats.红覆轮茶对大鼠细胞色素P450介导的代谢活性的影响。
In Vivo. 2018 Jan-Feb;32(1):33-40. doi: 10.21873/invivo.11201.
7
Effectiveness of the liver micronucleus assay using juvenile mice.使用幼年小鼠的肝脏微核试验的有效性。
J Vet Med Sci. 2017 Jul 28;79(7):1310-1317. doi: 10.1292/jvms.17-0116. Epub 2017 Jul 11.
8
In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin.旨在表征阿尼芬净清除机制及潜在细胞色素P450相互作用的体外和体内研究。
Antimicrob Agents Chemother. 2009 Mar;53(3):1149-56. doi: 10.1128/AAC.01279-08. Epub 2008 Nov 24.
9
Drug-induced liver graft toxicity caused by cytochrome P450 poor metabolism.细胞色素P450代谢不良引起的药物性肝移植毒性。
Br J Clin Pharmacol. 2008 Mar;65(3):428-36. doi: 10.1111/j.1365-2125.2007.03056.x. Epub 2007 Dec 7.
10
Pharmacological evaluation of C-3 modified Betulinic acid derivatives with potent anticancer activity.具有强效抗癌活性的C-3修饰桦木酸衍生物的药理学评价
Invest New Drugs. 2008 Feb;26(1):25-34. doi: 10.1007/s10637-007-9081-4. Epub 2007 Sep 13.